Cargando…
Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes
BACKGROUND: Diabetes mellitus is a risk for increased incidence of adverse clinical events after percutaneous coronary intervention. However, the difference in the incidence of adverse clinical events according to stent type in patients with diabetes remains to be elucidated. In the present study, w...
Autores principales: | Kakizaki, Ryota, Minami, Yoshiyasu, Katamine, Masahiro, Katsura, Aritomo, Muramatsu, Yusuke, Hashimoto, Takuya, Meguro, Kentaro, Shimohama, Takao, Ako, Junya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531093/ https://www.ncbi.nlm.nih.gov/pubmed/33004019 http://dx.doi.org/10.1186/s12933-020-01145-x |
Ejemplares similares
-
Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population
por: Gasior, Pawel, et al.
Publicado: (2021) -
Five‐Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus‐Eluting Stents Versus Durable Polymer Everolimus‐Eluting Stents
por: Iglesias, Juan F., et al.
Publicado: (2019) -
Safety and efficacy of biodegradable polymer-coated thin strut sirolimus-eluting stent vs. durable polymer-coated everolimus-eluting stent in patients with acute myocardial infarction
por: Gąsior, Paweł, et al.
Publicado: (2018) -
Ultrathin Strut Biodegradable Polymer Sirolimus‐Eluting Stent Versus Durable‐Polymer Everolimus‐Eluting Stent for Percutaneous Coronary Revascularization: 2‐Year Results of the BIOSCIENCE Trial
por: Zbinden, Rainer, et al.
Publicado: (2016) -
Clinical outcomes of biodegradable polymer biolimus-eluting BioMatrix stents versus durable polymer everolimus-eluting Xience stents
por: Lee, Da Hyon, et al.
Publicado: (2017)